
|Articles|August 15, 2002
- BioPharm International-08-01-2002
- Volume 15
- Issue 8
Making Regulatory Compliance a Core Process: Director and Officer Liability Exposure
by Joseph F. Noferi, Edward R. Arling, and Ralph H. Dillon, Pharmacia GS API Biopharma, global supply, and Daniel E. Worden, Worden Enterprises FDA is no longer complacent, punishing noncompliant companies with puny fines, those small slaps at the financial bottom line. FDA?s thunder now includes multimillion dollar fines, permanent injunctions, and prison sentences for senior executives. Companies that emerge as winners in today?s environment are those that treat compliance and risk management with the same flawless planning and execution that they use for their business plans and their financial investments.
Advertisement
Articles in this issue
over 24 years ago
Guest Editorial: Quality Agreements with Contract Laboratoriesover 24 years ago
Your Vested Interests: Gorillas In Our MidstAdvertisement
Related to this article

FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.

Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.

Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.

Commit Biologics Raises $60 Million to Take Complement-Powered Immune Engager COM002 Into the Clinic
Danish biotech Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to advance COM002, a bispecific antibody that recruits complement rather than T cells to eliminate diseased cells.

FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.

Galinpepimut-S maintenance extended median overall survival to 24.0 vs 14.7 months in transplant-ineligible AML patients in second or later remission.

Mazen Noureddin, MD, MHSc, discusses phase 2 data for GSK’s once-monthly efimosfermin presented at The Liver Meeting 2026, including fibrosis marker results in patients with compensated cirrhosis.
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Rejects Summit’s PD-1×VEGF Bispecific Ivonescimab in EGFR-Mutated NSCLC, Citing Lack of Survival Benefit
2
Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts
3
FDA Approves AstraZeneca's Gefurulimab (Klygefa) for Generalized MG
4
FDA's Rare Disease Framework Aims for Consistency Across Review Divisions, Says Former FDA Reviewer Paz Vellanki
5


